Objective-To evaluate if p53 decreases Kruppel-Like Factor 2 (KLF2) expression and determine whether p53-mediated suppression of KLF2 plays a role in p53-induced endothelial dysfunction. Methods and Results-Endothelial KLF2 mediates endothelium-dependent vascular homeostasis by differentially regulating endothelial genes, leading to an anti-inflammatory and antithrombotic endothelial surface with normal vasodilatory function. In contrast, the tumor suppressor p53 leads to inflammatory gene expression and impairs endothelium-dependent vasodilatation, thus promoting endothelial dysfunction. The effect of p53 on KLF2 expression was determined. p53 inhibited KLF2 transcription in a histone deacetylase-dependent and a histone acetyltransferaseindependent fashion. KLF2 expression was suppressed by p53 via a conserved p53-binding repressor sequence in its promoter. p53 bound to, and stimulated, deacetylation of Histone H3 at the KLF2 promoter. The effect of p53 on endothelial KLF2 target genes was examined. Downregulation of p53 increased expression of endothelial NO synthase and thrombomodulin and inhibited expression of plasminogen activator inhibitor 1. Conversely, overexpression of p53 suppressed endothelial NO synthase and thrombomodulin expression and stimulated plasminogen activator inhibitor 1 and endothelin-1 expression. Knockdown of KLF2 abolished the p53-induced decrease in thrombomodulin and increase in endothelin-1. Both, overexpression of p53 and knockdown of KLF2 in endothelial cells increased blood coagulation on an endothelial cell monolayer. The p53-induced increase in coagulation was rescued by forced expression of KLF2. p53 also impaired endothelium-dependent vasodilatation and decreased bioavailable vascular NO, both of which were rescued by forced KLF2 expression. Conclusion-These findings illustrate a novel p53-dependent mechanism for the regulation of endothelial KLF2 expression. In addition, they show that downregulation of KLF2, in part, mediates a p53-stimulated dysfunctional endothelium. (Arterioscler Thromb Vasc Biol. 2011;31:133-141.)
T he Kruppel-Like factor (KLF)/Sp is a subclass of the zinc finger family of DNA-binding transcriptional factors. There are 17 KLF Factors (KLF1-KLF17) and 4 Sp factors (S1-S4). These family members are characterized by DNA binding domains containing the conserved sequence CX2CX3FX5LX2HX3H (X is any amino acid; underlined cysteine and histidine residues coordinate zinc binding). 1 Members of this family can bind to the consensus DNA sequence CACCC. One member of this family, lung KLF/ KLF2, is highly expressed in vascular endothelium and serves as a molecular switch to regulate a range of endothelial functions. KLF2 expression in the endothelium is upregulated by laminar shear stress and inhibited by proinflammatory cytokines. 2, 3 Forced expression of KLF2 in endothelial cells results in induction of endothelial-specific NO synthase (eNOS) and thrombomodulin (TM) expression while abrogating cytokine-mediated expression of vascular cell adhesion molecule-1 and tissue factor. 4, 5 In addition, KLF2 inhibits endothelial cell migration and angiogenesis; this is partly attributed to its ability to inhibit VEGF receptor (VEGFR) 2/kinase insert domain containing receptor (KDR) expression. 5 KLF2 also protects endothelial cells from oxidative stress-mediated injury and apoptosis, 3 which is consistent with the capacity of endothelial KLF2 to regulate cellular levels of reactive oxygen species. 6 The p53 tumor suppressor gene is a transcription factor that is induced and activated in response to various cellular stresses. It plays a crucial role in coordinating cell cycle arrest and apoptosis in response to such stresses. 7 Whether vascular p53 promotes or retards the atherosclerotic process remains controversial. p53 Expression has been reported in vascular smooth muscle cells, endothelial cells, and macrophages of human atherosclerotic lesions; however, it is undetectable in normal vascular specimens. 8 Super p53-transgenic mice carrying an extra allele of p53 have decreased neointimal thickening induced by mechanical injury but are not protected from diet-induced atherosclerosis. 9 These findings and observations that p53 deletion in apolipoprotein E Ϫ/Ϫ mice lead to increased aortic atherosclerosis in response to a high-fat diet further support a role for p53 in retarding atherosclerosis. 10 Such a role for p53 in retarding atherosclerosis and neointima formation has been attributed to an increased rate of cell proliferation and reduced apoptosis in multiple cell types in the plaques of p53-deficient mice. On the other hand, p53 in the endothelium promotes oxidative stress and impairs endothelium-dependent vasorelaxation, suggesting that in this context it may promote atheroma formation. 11 Finally, although the role of p53 in vascular inflammation has not been examined, p53 does stimulate inflammatory signaling and inflammatory gene expression in several cell types. 12, 13 Transcriptional regulation of KLF2 expression is complex. Most studies have examined 140 bp of the proximal promoter of KLF2, 14, 15 a region that is highly conserved between mouse and human. Within this region, a binding site for the myocyte-enhancing factor (MEF) 2 transcription factor plays a pivotal role in the regulation of KLF2 expression in endothelial cells induced by several stimuli. 2, 3, 16, 17 In addition to MEF2, additional mechanisms have been implicated in the flow-mediated induction of KLF2. For example, P300/ CREB-binding protein (CBP)-associated factor (PCAF), heterogeneous nuclear ribonucleoprotein D, and nucleolin have all been identified as factors that bind to the proximal KLF2 promoter as part of a shear stress regulatory complex. 14, 15 Recognizing that endothelial p53 impairs vasorelaxation and that KLF2 has salutary effects on endothelial function, we hypothesized that p53 may exert some of its deleterious effects on endothelium-dependent vascular function by suppressing endothelial expression of KLF2. By using overexpression and knockdown approaches we provide evidence that p53 transcriptionally downregulates KLF2 expression and demonstrate that this downregulation is responsible for some of the phenotypic changes induced by p53 in the endothelium.
Methods

Cell Culture and Reagents
The following items were commercially obtained: human umbilical vein endothelial cells (HUVECs), 293 cells, antibodies recognizing p53 (DO-1), ␤-actin, TM, plasminogen activator inhibitor (PAI-1), anti-p53 (Pab-421), anti-acetylated p53, anti-acetylated histone 3 (H3), methyl methanesulfonate (MMS), and tumor necrosis factor ␣. The following items were gifts: human carcinoma cell line (HCT) 116 cells and anti-KLF2 antibody. Ad (adenovirus)-Betagalactosidase gene (LacZ), Ad-p53, and Ad-KLF2 adenoviruses have been previously described. 4, 18 KLF2 promoter firefly luciferase reporter constructs have been previously described. 2 Additional 117-and 88-bp fragments of KLF2 proximal promoters were generated by PCR and subsequently cloned in pGL3 firefly luciferase reporter. Previously described point mutations in the MEF2 site 2 were created in full-length KLF2 promoter using a site-directed mutagenesis kit. The 27-bp putative p53-response element was deleted and replaced by the restriction site sequence TTACGCGTGCTAGCCCGGGCTCGAG in full-length KLF2 promoter by restriction digestion. All deletions and mutations were confirmed by sequencing. Expression plasmid for p53 in pCMV vector backbone was a gift, as were mutant p53 plasmids (p53-H175 and p53-H175A392) and super repressor inhibitor of B pathway (SR-IB␣) plasmid.
Transient Transfection Reporter Assays
Cells were plated at a density of 5ϫ10 4 per well in 24-well plates 1 day before transfection. Transient transfection was performed using Lipofectamine2000. A total 1 to 2 g of plasmid DNA was used in transfections, and total DNA was kept constant. Cotransfected Renilla luciferase was used as an internal control. Cells were harvested 24 hours after transfection, firefly and Renilla luciferase activity was measured using a dual luciferase reporter kit, and firefly values were normalized to Renilla values in each sample. All transfections were performed in triplicate, and results are representative of at least 3 independent experiments.
Immunoblotting
Protein lysates were boiled in SDS-PAGE gel-loading buffer, subjected to SDS-PAGE, transferred to a nitrocellulose filter, and probed with the specified primary antibody and the appropriate peroxidase-conjugated secondary antibody. The chemiluminescent signal was developed using a substrate (Super Signal West Femto), blots were imaged with an imaging system (Gel Doc 2000 Chemi Doc system), and bands were quantified using computer software (Quantity One).
Electrophoretic Mobility Shift Assays
Electrophoretic mobility shift assays were performed as previously described. 2 Approximately 5 g of the nuclear extract was used in each incubation. A radiolabeled nucleotide (5Ј-CCAGGCTTATAT-ACCGCG GCTAAATTTAGGCTGAGCCCGGA-3Ј) corresponding to the putative p53 binding site in the KLF2 promoter was used. Anti-p53 (Pab-421) or unlabeled oligonucleotide was preincubated with nuclear extract for the supershift and competition, respectively.
Small Interfering RNA Transfection
Human p53 and KLF2 small interfering RNAs (siRNAs) and a nonspecific control siRNA were purchased commercially and transfected into HUVECs using Lipofectamine2000, according to the manufacturer's protocol.
Real-Time RT-PCR
Total RNA from cultured cells was isolated using a reagent (TRIZOL). Real-time PCR was performed using a detection system (Prism 7000 Sequence Detection System) with a kit (SuperScript III Platinum SYBR Green One-Step qRT-PCR Kit). The following primers were used: (1) human KLF2 (forward, 5Ј-tgcggcaagacctacaccaagagt-3Ј; reverse, 5Јagccgcagccgtcccagtt-3Ј), (2) human p53 (forward, 5Ј-ttgagcactacagacctcacg-3Ј; reverse, 5Ј-tgcaccagtatttccaatcaa-3Ј), (3) human eNOS (forward, 5Ј-ctcatg ggcacggtgatg-3Ј; reverse, 5Ј-accacg tcatactcatccatacac-3Ј), (4) human TM (forward, 5Ј-tgagcgttattggtcggcagcct-3Ј; reverse, 5Ј-cacaggtagggtgactcagg-3Ј), (5) human PAI-I (forward, 5Јgcatgacctaccaggacagaact-3Ј; reverse, 5Ј-tccgagctgcctgtctctct-3Ј), (6) human GAPDH (forward, 5Ј-ccacatcgctcagacaccat-3Ј; reverse, 5Јccaggcgcccaatacg-3Ј), and (7) human endothelin (ET)-1 (forward, 5Ј-tggacatcatttgggtcaaca-3Ј; reverse, 5Ј-tctcttggacctagggcttcc-3Ј).
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation assays were performed using a kit (ChIP Assay Kit) and indicated antibodies. 2 In brief, DNA associated with specific immunoprecipitates or with negative control mouse non-immune IgG was isolated and used as a template in a PCR reaction amplifying a 169-bp region of the KLF2 promoter with the putative p53-binding element or the GAPDH gene. Primer sequences were as follows: KLF2, forward, 5Ј-gcagtccgggctcccgcagtag-3Ј; and reverse, 5Ј-cttataggcgcggcaggcac-3Ј; and GAPDH, forward, 5Ј-atgacatcaagaaggtggtg-3Ј; and reverse, 5Ј-cataccaggaaatgagcttg-3Ј.
Ex Vivo Adenoviral Infection of Rat Aortic Rings
Aortic rings from 3-to 4-month-old Wistar Kyoto rats were incubated with the specified adenovirus ex vivo for 24 hours, as previously described, 19 before measurement of vascular reactivity.
In Vitro Clotting Assay
HUVECs were plated in 96-well dishes and infected with indicated adenovirus for 48 hours. Cells were rinsed twice with warm PBS and 100 L of 37°C human plasma added to each well. Immediately afterward, 100 L of 25-mm calcium chloride was added, and plates were placed in a Perkin Elmer kinetic plate reader and read at 405 nm every 20 seconds for 30 minutes. 20 Fibrin clot formation is indicated when maximum absorbance is reached. Clotting times are reported at half-maximal absorbance.
Vascular Reactivity Measurement
Rats, aged 3 to 4 months, were anesthetized using ketamineacepromazine (100 and 10 mg/kg IP, respectively). The animals were rapidly euthanized by cardiac excision. The thoracic aorta was carefully dissected, rapidly removed, and placed in ice-cold oxygenated Krebs-Ringer's bicarbonate solution. The vessel was carefully cleared of loose connective tissue. It was then cut into 5 to 10 rings (size, 1.5 mm). A single ring from each rat was suspended between 2 wire stirrups (150 m) in 1 of the 25-mL organ chambers of the 4-chamber myograph system in 5-mL Krebs-Ringer's solution (95% O 2 -5% CO 2 , pH 7.4, 37°C). One stirrup was connected to a 3D micromanipulator, and the other was connected to a force transducer. The mechanical force signal was amplified, digitalized, and recorded (PowerLab 8/30). All concentration-effect curves were performed on arterial rings beginning at their optimum resting tone. This was determined by stretching arterial rings at 10-minute intervals in increments of 500 mg to reach optimal tone (approximately 3000 mg). One dosage of potassium chloride (60 mmol/L) was administered to verify vascular smooth muscle viability. A cumulative dose-response curve for phenylephrine (10 Ϫ9 -10 Ϫ5 mol/L) was obtained by administering the drug in half-log doses. Endotheliumdependent and endothelium-independent vasodilatations were determined by generating dose-response curves to acetylcholine (10 Ϫ9 -10 Ϫ5 mol/L) and sodium nitroprusside (10 Ϫ9 -10 Ϫ5 mol/L), respectively. Vasorelaxation evoked by acetylcholine and sodium nitroprusside is expressed as percentage relaxation, determined by the percentage of inhibition to the preconstricted tension. NO bioavailability was measured physiologically by determining the increase in contractile response to NOS inhibition (L-Nitro-L-Arginine Methyl Ester [L-NAME], 10 Ϫ4 mol/L) in rings preconstricted with phenylephrine (10 Ϫ6 mol/L).
Results p53 Inhibits KLF2 Expression
To determine whether p53 regulates KLF2, we first compared KLF2 expression in the HCT116 p53 ϩ/ϩ colon cancer cell line and its isogenic p53 Ϫ/Ϫ cell line. KLF2 expression, both at the mRNA ( Figure 1A ) and protein ( Figure 1B ) levels, was significantly higher in p53 Ϫ/Ϫ HCT116 cells when compared with p53 ϩ/ϩ HCT116 cells, suggesting transcriptional downregulation of KLF2 by p53. To determine whether a similar role for p53 exists in endothelial cells, KLF2 expression was assessed in HUVECs after siRNA-mediated downregulation of p53. Knockdown of p53 in HUVECs was accompanied by upregulation of KLF2 expression at the mRNA and protein levels ( Figure 1C and 1D, respectively). Thus, p53 inhibits KLF2 expression at the transcriptional level.
To examine if KLF2 downregulation by p53 leads to a change in endothelial KLF2 target genes, we measured the expression of TM and eNOS, genes that are upregulated by KLF2; and PAI-1, a gene that is downregulated by KLF2. Knockdown of p53 in HUVECs led to an increase in TM and eNOS expression levels and a decrease in PAI-1 expression ( Figure 1D ). Conversely, adenoviral overexpression of p53 in HUVECs decreased KLF2, eNOS, and TM expression levels while increasing PAI-1 and ET-1 expression levels (Figure 2A-2D ). Thus, in keeping with its effect on KLF2 expression, p53 also affects KLF2 target genes in endothelial cells.
Next, we determined the mediating role of KLF2 in p53-induced suppression or induction of KLF2 target genes. The effect of p53 overexpression on endothelial TM and ET-1 expression in cells in which KLF2 was knocked down was examined. Compared with control siRNAtransfected cells, adenoviral p53 overexpression in KLF2 siRNA-transfected HUVECs did not lead to a decrease in TM expression ( Figure 2C ). Similarly, p53 overexpression did not increase ET-1 expression in endothelial cells in which KLF2 was knocked down ( Figure 2D ). Thus, KLF2 mediates p53-induced regulation of TM and ET-1 expression in endothelial cells.
Next, we asked if an extrinsic stimulus that activates p53 also represses KLF2 expression. Some genotoxic agents lead to cell death or cell cycle arrest by increasing p53 expression or inducing posttranslational modifications on p53 that increase its DNA binding activity. 21 We investigated the effect of the genotoxic drug MMS on KLF2 expression and asked whether p53 mediates this effect. MMS stimulated acetylation of p53 in the colon cancer cell line HCT116 p53 ϩ/ϩ ( Figure 3A ). In addition, HCT116 p53 ϩ/ϩ cells challenged with MMS displayed decreased expression of KLF2 at the RNA ( Figure 3A ) and protein ( Figure 3B ) levels. However, MMS-induced decrease in KLF2 expression was completely abolished in the p53-deficient (p53 Ϫ/Ϫ ) HCT116 cell line ( Figure 3A and 3B). Similarly, in endothelial cells, siRNAmediated knockdown of p53 abrogated the downregulation of KLF2 and the upregulation of the KLF2 target gene PAI-1 by MMS ( Figure 3C ). Taken together, these data show that p53 is indispensable for genotoxic stress-induced downregulation of KLF2.
p53 Regulates KLF2 Promoter Activity Via a Novel p53 Response Element
Next, we assessed the effect of p53 on KLF2 promoter activity. A 1659-bp region upstream of the transcription start site (Ϫ1659) in the KLF2 gene was used in promoterreporter assays. P53 inhibited KLF2 promoter activity ( Figure 4A ). In contrast, 2 DNA-binding-deficient mutants of p53 (H175p53 and HA175A392p53) that act in a dominant inhibitory fashion increased KLF2 promoter activity. These findings indicate a role for p53 in suppressing KLF2 transcription.
A previous study 12 has suggested that p53 can modulate nuclear factor (NF)-B expression and function. Given the importance of NF-B in regulating cytokine-stimulated repression of KLF2 expression, 2 we examined the role of NF-B in p53-induced downregulation of KLF2. NF-B activity was inhibited using SR-IB␣. Expression of SR-IB␣ did not inhibit p53-stimulated repression of KLF2 promoter activity ( Figure 4B ). In contrast, SR-IB␣ abolishes a tumor necrosis factor ␣-induced decrease in KLF2 promoter activity ( Figure  4B) , consistent with the role of NF-B in mediating tumor necrosis factor ␣-stimulated repression of KLF2 transcription. 2 We also examined the role of NF-B in mediating p53-induced repression of KLF2 transcription by creating KLF2 promoter-reporter constructs that are devoid of putative NF-B response elements. Four putative NF-B sites in the 1659-bp KLF2 promoter were identified and sequentially deleted or mutated. The lack of these putative NF-B sites did not affect p53-induced repression of the KLF2 promoter ( Figure 4C ). These findings demonstrate the dispensability of NF-B in p53-induced downregulation of KLF2 transcription.
The core KLF2 promoter consists of a 221-bp region upstream of the transcription start site and is highly conserved in mice and humans. This region has an MEF2 binding site ( Figure 4D ) that plays a critical role in governing KLF2 expression regulated by laminar flow, 3 cytokines, 2 and statins. 5, 17 We examined the role of the MEF2 response element in p53-induced repression of KLF2 transcription by mutating key nucleotides in it and measuring p53-stimulated repression of the mutated and wild-type full-length promot- ers. Mutation of the MEF2 response element did not affect basal or p53-stimulated inhibition of promoter activity (Figure 4E) . Thus, the MEF2 site is dispensable for repression of KLF2 promoter activity by p53.
Armed with the knowledge that the core 221-bp promoter is sufficient for repression of promoter activity by p53 and that the MEF2 response element is dispensable for p53stimulated trans-repression, we sought novel p53 response elements in this region of the promoter. An examination of the promoter sequence reveals a 27-bp element resembling the p53 consensus binding site ( Figure 4D ). To determine whether this 27-bp element functions as a p53 response element, we deleted it in the full-length promoter and measured the response to p53. Deletion of this element completely abrogated p53-stimulated repression of the KLF2 promoter ( Figure 4E ). We also generated 2 additional promoters-reporters: one that encompasses this element (117) and one in which this 27-bp element is deleted (Ϫ88). We then compared p53-stimulated activity of the Ϫ221, Ϫ117, and Ϫ88 promoters. Compared with the Ϫ221 core promoter, p53 suppressed activity of the Ϫ117 promoter to a similar degree (supplemental Figure I ; available online at http://atvb.ahajournals.org). However, p53 did not inhibit activity of the Ϫ88 promoter (supplemental Figure II) . Taken together, these findings show that this 27-bp sequence in the KLF2 promoter is a p53 response element required for p53-stimulated repression of KLF2 promoter activity.
p53 Binds to the KLF2 Promoter
Next, we examined whether p53 binds to this 27-bp element in the KLF2 promoter. First, we performed electrophoretic mobility shift assays using nuclear extract from human embryonic kidney (HEK) 293 cells overexpressing p53 and radiolabeled oligonucleotide with a sequence corresponding to the 27 nucleotides of this element. Nuclear extract containing p53 formed complexes with the labeled oligonucleotide, one of which was identified as containing p53 using unlabeled excess oligonucleotide and p53-specific antibody ( Figure 4F ). Thus, p53 binds in vitro to an oligonucleotide corresponding to the p53 response element in the KLF2 promoter.
Next, we examined occupancy by p53 of the region of the KLF2 promoter containing this element. Chromatin immunoprecipitation assays amplifying a 169-bp region of the human KLF2 promoter, which encompasses the p53 response element, showed that p53 occupies this genomic region in the KLF2 promoter. Therefore, p53 occupies the KLF2 promoter in the genomic context ( Figure 4G ).
P53 Induces Hypoacetylation of Histone H3 on the KLF2 Promoter and Suppresses KLF2 Transcription in a Histone Acetyltransferase-Independent and a Histone Deacetylase-Dependent Manner
Next, we investigated how p53 represses KLF2 expression. P300/CBP and PCAF are histone acetyltransferases that acetylate histone and nonhistone proteins on lysine residues. Through acetylation, p300/CBP and PCAF increase the transcription of various genes and also relieve gene repression, 22 such as in vertebrate homologues of Caenorhabditis elegans protein SMA and MAD-3 (Smad3)-induced repression of proinflammatory target genes. 23 We considered the possibility that the p53-mediated repression of KLF2 transcription may occur through sequestration of coactivators, such as p300/CBP and PCAF. To investigate this possibility, we examined the effect of p300 and PCAF overexpression on p53-induced repression of KLF2 promoter activity. P300 independently stimulated KLF2 promoter activity, indicating that it can function as a coactivator of KLF2 transcription ( Figure 5A) . Similarly, PCAF stimulated KLF2 promoter activity ( Figure 5B ). However, neither p300 nor PCAF overexpression rescued p53induced repression of KLF2 promoter activity ( Figure 5A and  5B) . Thus, sequestration of p300 or PCAF by p53 cannot explain the p53-stimulated decrease in KLF2 transcription.
Next, we focused our attention on recruitment of transcriptional repressors by p53 to the KLF2 promoter. The histone deacetylases (HDACs) constitute a major category of enzymes that repress gene expression. HDACs deacetylate histone proteins leading to a compact chromatin structure and a decrease in gene transcription. 24 p53 Associates with and recruits HDACs to various gene promoters to regulate gene expression. 25 Therefore, we assessed the role of HDACs as corepressors that are recruited by p53 to the KLF2 promoter and mediate p53-induced repression of KLF2 transcription. We first examined the effect of HDAC inhibition on p53-induced suppression of KLF2 expression. Trichostatin A, an inhibitor of class I and II HDACs, abrogated the p53-induced decrease in KLF2 expression in endothelial cells ( Figure 5C ). Moreover, trichostatin A blocked the p53-induced decline in KLF2 promoter activity ( Figure 5D ). Thus, inhibition of class I and II HDACs antagonizes p53induced repression of KLF2 transcription, suggesting that one or more members of these classes of HDACs play a role in p53-induced repression of KLF2 transcription.
Wild-type p53 binds to its target genes and recruits corepressor HDACs that subsequently modify histone H3 and H4 and decrease gene expression. 26, 27 Therefore, the recruitment of HDACs by p53 to the KLF2 promoter would be expected to lead to hypoacetylation of histones at the KLF2 promoter. Thus, we asked if p53 stimulates hypoacetylation of histones at the KLF2 promoter. Chromatin immunoprecipitation experiments were performed to determine the p53-mediated change in acetylation of Histone H3 at the KLF2 promoter. Acetylation on lysine 9 of Histone H3 at the KLF2 promoter was significantly lower in p53 ϩ/ϩ HCT166 cells when compared with p53 Ϫ/Ϫ HCT116 cells ( Figure 5E ). Thus, p53 leads to hypoacetylation of H3 at the KLF2 promoter and indicates a role for recruitment of HDACs by p53 to the promoter.
p53 Promotes a Prothrombotic Endothelial Cell Phenotype and Impairs Endothelium-Dependent NO Production by Repressing KLF2 Expression
TM and PAI-1, 2 target genes of KLF2, are important modulators in the coagulation cascade. TM expression by the endothelium inhibits thrombosis, 28 whereas PAI-1 expression on the endothelium promotes blood clotting. 29 Therefore, the increase in endothelial PAI-1 and the decrease in TM expression induced by p53 would be expected to lead to a prothrom- . p53 Binds to the KLF2 promoter and regulates its activity. A, p53 Represses KLF2 promoter activity. The activity of the Ϫ1659-bp KLF2 promoter-reporter construct was measured in HEK 293 cells with and without expression of wild-type p53 or dominant-negative mutants of p53 (H175 and H175A392). Normalized (firefly/Renilla) promoter activity is expressed relative to cells not expressing p53 (*PϽ0.05, nϭ3). B and C, p53-induced inhibition of KLF2 promoter activity is NF-B independent. In B, activity of Ϫ1659-bp KLF2 promoter was measured in HEK 293 cells in the presence of p53, SR-IB␣, or tumor necrosis factor (TNF)-␣ alone or in combination, as indicated. Normalized (firefly/Renilla) promoter activity is expressed relative to vector-transfected control (*PϽ0.05 and **PϽ0.01, nϭ3). In C, activity of the indicated KLF2 promoter-reporter constructs with sequential deletions of putative NF-B response elements were measured in HEK 293 cells with and without expression of p53. Normalized (firefly/Renilla) promoter activity is expressed relative to cells not expressing p53 (*PϽ0.05 and **PϽ0.01, nϭ3). D and E, p53 mediates KLF2 repression through p53 response element. In D, a schematic representation of the 27-bp p53 response element in the KLF2 promoter is shown. The consensus p53 response element is also shown. Pu indicates purines; Pr, pyrimidine; N, any nucleotide. In E, activity of wild-type MEF2-Mut (MEF2 site AATT mutated to TCGG) or p53-del (27 bp of p53 response element deleted) of KLF2 promoters (Ϫ1659/ϩ1KLF2) was measured in 293 cells in the presence or absence of p53. Luciferase activities are expressed relative to wild-type KLF2 promoter. F and G, p53 binds to the p53 response element in the KLF2 promoter. In F, p53 binds in vitro to an oligonucleotide with a sequence botic endothelial phenotype. To test this, we performed an in vitro thrombosis assay on an endothelial cell monolayer. Adenoviral overexpression of p53 in endothelial cells decreased the time to thrombosis ( Figure 6A ), indicating that p53 promotes a prothrombotic phenotype in endothelial cells. This p53-induced prothrombotic phenotype was rescued by forced adenoviral expression of KLF2 ( Figure 6A ). In contrast, siRNA-mediated knockdown of KLF2 in endothelial cells decreased the time to clot formation under basal conditions, and also potentiated the p53-induced decrease in time to clot formation ( Figure 6B ). These findings show an important role for KLF2 repression in the p53-induced prothrombotic phenotype in endothelial cells.
Endothelial p53 impairs endothelial-dependent vascular relaxation. 11 In contrast, endothelial KLF2 increases the expression of eNOS and inhibits ET-1 expression, leading to vasodilatation. 4 This prompted us to ask if impairment of endotheliumdependent vasorelaxation by p53 is also, in part, the result of downregulation of KLF2. Ex vivo vasoreactivity studies in rat aortas demonstrated that adenoviral overexpression of p53 im- p53-induced repression of KLF2 promoter activity is independent of HAT. In A, overexpression of the p300 HAT is unable to rescue p53-induced repression of KLF2 promoter activity. KLF2 promoter activity was measured in HEK 293 cells with and without expression of p53 and p300, alone or in combination. Normalized reporter activity is expressed relative to vector control (*PϽ0.05, nϭ3). In B, overexpression of the PCAF HAT is unable to rescue p53-induced repression of KLF2 promoter activity. KLF2 promoter activity was measured in HEK 293 cells with and without expression of p53 and PCAF, alone or in combination. Normalized reporter activity is expressed relative to vector control (**PϽ0.01, nϭ3). C and D, p53 inhibits KLF2 expression in an HDAC-dependent manner. In C, p53-induced downregulation of KLF2 expression is rescued by the class I and II HDAC inhibitor trichostatin A (TSA). HUVECs pretreated with TSA (500 nmol/L) for 4 hours were infected with an adenovirus encoding p53 (Adp53) or a control adenovirus encoding LacZ (AdLacZ). Representative immunoblots are shown (nϭ3). In D, p53induced repression of KLF2 promoter activity is rescued by TSA. KLF2 promoter activity was measured in HEK 293 cells with and without expression of p53 and treatment with TSA (500 nmol/L). Normalized reporter activity is expressed relative to vector control (**PϽ0.01, nϭ3). E, p53 decreases acetylation of H3 associated with the KLF2 promoter. A chromatin immunoprecipitation (ChIP) assay was performed on chromatin from HCT116 p53 ϩ/ϩ and HCT116 p53 Ϫ/Ϫ cells with acetylated H3 (Ac-H3) antibody (lanes 4 and 6) or nonimmune IgG (lanes 3 and 5), and a 169-bp region of KLF2 promoter was PCR amplified. Nonimmunoprecipitated chromatin was used as an input (lanes 1 and 2). Amplification of GAPDH in immunoprecipitates was used as a specificity control. Data are representative of 3 experiments, and representative immunoblots are shown. pairs acetylcholine-induced endothelium-dependent vasorelaxation ( Figure 6C ) and decreases bioavailable vascular NO ( Figure 6D ) but does not affect endothelium-independent vasorelaxation ( Figure 6E ). Forced adenoviral coexpression of KLF2 rescued impairment of endothelium-dependent vasorelaxation ( Figure 6C ) and decreased vascular bioavailable NO ( Figure 6D ) induced by p53. These findings show that downregulation of KLF2 is, in part, responsible for p53-induced impairment of endothelium-dependent production of NO and vasorelaxation.
Discussion
Endothelial dysfunction that includes impaired vasodilatation, and increased expression of adhesion molecules and procoagulant factors, is an early pathophysiological event in the development and progression of cardiovascular diseases. P53 has been implicated in impairing endothelial function, whereas KLF2, by differentially regulating endothelial gene expression, is essential to the maintenance of an antithrombotic and vasodilatory endothelium. The major finding of the present study is that KLF2 is a gene that is targeted and repressed by p53; this functional relationship between the 2 has a bearing on p53-induced impairment of normal endothelial function.
We considered several plausible mechanisms by which p53 may regulate KLF2 transcription. A previous study 12 showed that NF-B acts as a downstream effector of p53. Our studies with the molecular inhibitor of NF-B (SR-IB) and promoter deletion analysis (constructs devoid of putative NF-B binding sites) provide evidence that NF-B-mediated signaling is not involved in p53-induced repression of KLF2 transcription. Furthermore, because the element that mediates the response to p53 lies outside a region in the KLF2 promoter that includes the MEF2 binding site, our data also indicate that p53-induced KLF2 repression does not involve MEF2 factors that are known to be important for basal and cytokine-induced downregulation of KLF2. 2 As such, our findings provide an additional mechanism for transcriptional control of KLF2, showing the importance of a novel functional p53 response element in the KLF2 promoter. An examination of the p53 response element in the KLF2 promoter reveals an imperfect match with the consensus p53 binding motif, which consists of 2 half sites (5Ј-PuPuPuC (A/T)(T/A)GpyPyPy-3Ј) separated by 0 to 13 base pairs. Nevertheless, there are ample examples of p53 response elements that deviate from the consensus binding motif. 30 -32 Moreover, a comparison of the human and mouse KLF2 promoter sequences shows 100% homology of this p53 response element, suggesting that p53 has an important and conserved role in regulating of KLF2 transcription via this element.
Although well-known as a transcriptional activator, p53 also represses genes that are involved in various signaling pathways, such as cell proliferation (c-myc and cyclin B) and apoptosis (B-Cell lymphoma and survivin). 26, 33 For p53mediated gene repression, several mechanisms have been proposed. Repression may occur through displacement of coactivators by p53 from adjacent or overlapping binding sites within the promoters. 25, 34 Alternatively, p53 may recruit transcriptional corepressors to specific promoters to inhibit their activity. 25, 34 P53-mediated repression that depends on HDAC recruitment requires additional protein(s), such as mSin3a. 34 Our data demonstrate that sequestration of p300/ PCAF away from the KLF2 promoter is not the mechanism for p53-induced repression of KLF2 transcription; rather, recruitment of HDACs as corepressors to the KLF2 promoter mediates the effect of p53. This is supported by findings that the HDAC inhibitor trichostatin A abrogates downregulation of KLF2 expression by p53 and that p53 decreases lysine acetylation of Histone H3 at the KLF2 promoter and is consistent with a previous study 35 showing that p53 represses gene expression by decreasing Histone H3 acetylation through recruitment of HDACs.
Our findings indicate that KLF2 is the principal KLF that mediates p53-induced dysregulation of the endothelium. However, it is highly improbable that the p53-stimulated endothelial cell phenotype is solely via downregulation of KLF2. P53 influences the expression of a vast array of genes, many of which could, directly or indirectly, mediate some of the p53-induced phenotypes in endothelial cells. There is significant redundancy in the KLF family of transcription factors. KLF4 is capable of conferring gene-regulatory effects, similar to KLF2 in endothelial cells. 36 Thus, the KLF2-mediated effect of p53 may be blunted by the compensatory expression of other members of the KLF family. Impaired NO production is the sine qua non of endothelial dysfunction and is considered an early requisite step in the development of atherosclerotic vascular lesions. 37 Deficiency in endothelium-derived NO leads to impaired vasodilatation, increased proliferation and migration of smooth muscle cells, and platelet activation and aggregation, predisposing to thrombogenesis. 38 In recent years, though p53 has gained considerable attention for its role in atherosclerosis, this role still remains controversial. Yet, there is a paucity of information about how p53 affects endothelial function. p53 Expression is associated with increased apoptosis in endothelial and vascular smooth muscle cells 39 and impairs endothelialdependent vasorelaxation. 11 However, whether p53 affects thrombosis is not known. By showing that p53 inhibits KLF2, a pivotal endothelial factor that is important to NO production and one that promotes a milieu on the endothelium that inhibits thrombosis, our findings provide a unifying mechanism through which p53 in the endothelium affects both thrombosis and vascular tone. Finally, given the importance of p53 and KLF2 in regulating death, survival, and proliferation of many cell types, these observations may have broader implications for p53-mediated pathophysiological states.
